Skip to content

Study · Observational study · n = 120 · 2026

14 results

Real-world weight loss with injectable semaglutide vs dulaglutide for diabetes.

Spitery A, Lobkovich A, Thomas E

The American journal of managed care1 Jun 2026

PMID42335260 (opens in a new tab)DOI10.37765/ajmc.2026.89952 (opens in a new tab)PepBankPUB-42335260
Publisher pagePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, weight fell more with semaglutide than with dulaglutide at 52 weeks (-6.51% vs -1.14%).

    In plain wordsIn adults with type 2 diabetes, people on semaglutide lost more weight than people on dulaglutide over 52 weeks in a clinic record review.

    Peptide
    Semaglutide
    Outcome
    DecreasePercentage change in actual body weight at 52 weeks
    Study

    n = 120

    Comparator
    Dulaglutide
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · injectable · 52 weeksAs given in this study (human).

    Measurements

    Weight change
    −6.51%
    semaglutide
    Weight change
    −1.14%
    dulaglutide

    Source sentences

    Summary
    The percentage change in ABW from baseline at 52 weeks was greater with semaglutide (n = 60) than with dulaglutide (n = 60) (-6.51% vs -1.14%; P = .001).
    1 context sentence
    Summary · context
    This retrospective cohort study included adult patients with T2D at an academic internal medicine clinic who were initiated on semaglutide or dulaglutide.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, dulaglutide was linked to less percentage weight loss than semaglutide at 52 weeks.

    In plain wordsIn adults with diabetes, dulaglutide was linked to less percentage weight loss than semaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreasePercentage body weight change
    Study

    n = 120

    Comparator
    Semaglutide
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Measurements

    Body weight change
    −1.14%
    dulaglutide at 52 weeks
    Body weight change
    −6.51%
    semaglutide at 52 weeks

    Source sentences

    Summary
    The percentage change in ABW from baseline at 52 weeks was greater with semaglutide (n = 60) than with dulaglutide (n = 60) (-6.51% vs -1.14%; P = .001).
    1 context sentence
    Summary · context
    This retrospective cohort study included adult patients with T2D at an academic internal medicine clinic who were initiated on semaglutide or dulaglutide.
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, absolute weight change was greater with semaglutide than with dulaglutide at 52 weeks (-15.98 kg vs -4.93 kg).

    In plain wordsIn adults with type 2 diabetes, people on semaglutide lost more kilograms than people on dulaglutide over 52 weeks.

    Peptide
    Semaglutide
    Outcome
    DecreaseAbsolute change in body weight at 52 weeks
    Study

    n = 120

    Comparator
    Dulaglutide
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · injectable · 52 weeksAs given in this study (human).

    Measurements

    Weight change
    −15.98 kg
    semaglutide
    Weight change
    −4.93 kg
    dulaglutide

    Source sentences

    Summary
    The absolute change in ABW at 52 weeks was greater with semaglutide than with dulaglutide (-15.98 kg vs -4.93 kg; P = .001).
    1 context sentence
    Summary · context
    This retrospective cohort study included adult patients with T2D at an academic internal medicine clinic who were initiated on semaglutide or dulaglutide.
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, more patients on semaglutide than on dulaglutide achieved weight loss of at least 5% at 52 weeks (51.7% vs 25.0%).

    In plain wordsIn adults with type 2 diabetes, more people on semaglutide than on dulaglutide lost at least 5% of their weight in 52 weeks.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight loss of at least 5% at 52 weeks
    Study

    n = 120

    Comparator
    Dulaglutide
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · injectable · 52 weeksAs given in this study (human).

    Measurements

    Proportion with weight loss >=5%
    51.7%
    semaglutide
    Proportion with weight loss >=5%
    25%
    dulaglutide

    Source sentences

    Summary
    More patients using semaglutide achieved weight loss of at least 5% and at least 10% at 52 weeks than those using dulaglutide (≥ 5%: 51.7% vs 25.0%; P = .003; ≥ 10%: 31.7% vs 8.3%; P = .001).
    1 context sentence
    Summary · context
    This retrospective cohort study included adult patients with T2D at an academic internal medicine clinic who were initiated on semaglutide or dulaglutide.
  5. 05HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, more patients on semaglutide than on dulaglutide achieved weight loss of at least 10% at 52 weeks (31.7% vs 8.3%).

    In plain wordsIn adults with type 2 diabetes, more people on semaglutide than on dulaglutide lost at least 10% of their weight in 52 weeks.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight loss of at least 10% at 52 weeks
    Study

    n = 120

    Comparator
    Dulaglutide
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · injectable · 52 weeksAs given in this study (human).

    Measurements

    Proportion with weight loss >=10%
    31.7%
    semaglutide
    Proportion with weight loss >=10%
    8.3%
    dulaglutide

    Source sentences

    Summary
    More patients using semaglutide achieved weight loss of at least 5% and at least 10% at 52 weeks than those using dulaglutide (≥ 5%: 51.7% vs 25.0%; P = .003; ≥ 10%: 31.7% vs 8.3%; P = .001).
    1 context sentence
    Summary · context
    This retrospective cohort study included adult patients with T2D at an academic internal medicine clinic who were initiated on semaglutide or dulaglutide.
  6. 06HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, the proportion reaching HbA1c below 7% at 52 weeks did not differ significantly between semaglutide and dulaglutide (53.3% vs 38.3%; P = .100).

    In plain wordsIn adults with type 2 diabetes, the share reaching HbA1c below 7% was higher with semaglutide than dulaglutide, but not significantly.

    Peptide
    Semaglutide
    Outcome
    No significant changeHbA1c below 7% at 52 weeks
    Study

    n = 120

    Comparator
    Dulaglutide
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · injectable · 52 weeksAs given in this study (human).

    Measurements

    Proportion with HbA1c <7%
    53.3%
    semaglutide
    Proportion with HbA1c <7%
    38.3%
    dulaglutide

    Source sentences

    Summary
    (< 7%: 53.3% vs 38.3%; P = .100
    2 context sentences
    Summary · context
    Secondary outcomes included mean weight loss in kg, weight loss of at least 5% and at least 10% at 52 weeks, percentage change in hemoglobin A1c (HbA1c) at 52 weeks, and HbA1c levels of less than 7% and less than 8% at 52 weeks.
    Summary · context
    This retrospective cohort study included adult patients with T2D at an academic internal medicine clinic who were initiated on semaglutide or dulaglutide.
  7. 07HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, the proportion reaching HbA1c below 8% at 52 weeks did not differ significantly between semaglutide and dulaglutide (78.3% vs 68.3%; P = .220).

    In plain wordsIn adults with type 2 diabetes, the share reaching HbA1c below 8% was higher with semaglutide than dulaglutide, but not significantly.

    Peptide
    Semaglutide
    Outcome
    No significant changeHbA1c below 8% at 52 weeks
    Study

    n = 120

    Comparator
    Dulaglutide
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · injectable · 52 weeksAs given in this study (human).

    Measurements

    Proportion with HbA1c <8%
    78.3%
    semaglutide
    Proportion with HbA1c <8%
    68.3%
    dulaglutide

    Source sentences

    Summary
    < 8%: 78.3% vs 68.3%; P = .220
    1 context sentence
    Summary · context
    This retrospective cohort study included adult patients with T2D at an academic internal medicine clinic who were initiated on semaglutide or dulaglutide.
  8. 08HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, the absolute HbA1c change was greater with semaglutide than with dulaglutide at 52 weeks (-2.15% vs -1.36%).

    In plain wordsIn adults with type 2 diabetes, blood sugar control (HbA1c) improved more with semaglutide than with dulaglutide over 52 weeks.

    Peptide
    Semaglutide
    Outcome
    DecreaseAbsolute change in HbA1c at 52 weeks
    Study

    n = 120

    Comparator
    Dulaglutide
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · injectable · 52 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −2.15%
    semaglutide
    HbA1c change
    −1.36%
    dulaglutide

    Source sentences

    Summary
    The absolute change in HbA1c was greater with semaglutide than dulaglutide (-2.15% vs -1.36%; P = .033).
    1 context sentence
    Summary · context
    This retrospective cohort study included adult patients with T2D at an academic internal medicine clinic who were initiated on semaglutide or dulaglutide.
  9. 09HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, dulaglutide was linked to less absolute weight loss than semaglutide at 52 weeks.

    In plain wordsIn adults with diabetes, dulaglutide was linked to less weight loss in kilograms than semaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseAbsolute body weight change
    Study

    n = 120

    Comparator
    Semaglutide
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Measurements

    Body weight change
    −4.93 kg
    dulaglutide at 52 weeks
    Body weight change
    −15.98 kg
    semaglutide at 52 weeks

    Source sentences

    Summary
    The absolute change in ABW at 52 weeks was greater with semaglutide than with dulaglutide (-15.98 kg vs -4.93 kg; P = .001).
    1 context sentence
    Summary · context
    This retrospective cohort study included adult patients with T2D at an academic internal medicine clinic who were initiated on semaglutide or dulaglutide.
  10. 10HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, fewer dulaglutide users achieved at least 5% weight loss than semaglutide users at 52 weeks.

    In plain wordsIn adults with diabetes, fewer dulaglutide users lost at least 5% of body weight compared with semaglutide users.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseAt least 5% weight loss
    Study

    n = 120

    Comparator
    Semaglutide
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Measurements

    Responders
    25%
    dulaglutide: at least 5% weight loss
    Responders
    51.7%
    semaglutide: at least 5% weight loss

    Source sentences

    Summary
    More patients using semaglutide achieved weight loss of at least 5% and at least 10% at 52 weeks than those using dulaglutide (≥ 5%: 51.7% vs 25.0%; P = .003; ≥ 10%: 31.7% vs 8.3%; P = .001).
    1 context sentence
    Summary · context
    This retrospective cohort study included adult patients with T2D at an academic internal medicine clinic who were initiated on semaglutide or dulaglutide.
  11. 11HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, fewer dulaglutide users achieved at least 10% weight loss than semaglutide users at 52 weeks.

    In plain wordsIn adults with diabetes, fewer dulaglutide users lost at least 10% of body weight compared with semaglutide users.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseAt least 10% weight loss
    Study

    n = 120

    Comparator
    Semaglutide
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Measurements

    Responders
    8.3%
    dulaglutide: at least 10% weight loss
    Responders
    31.7%
    semaglutide: at least 10% weight loss

    Source sentences

    Summary
    More patients using semaglutide achieved weight loss of at least 5% and at least 10% at 52 weeks than those using dulaglutide (≥ 5%: 51.7% vs 25.0%; P = .003; ≥ 10%: 31.7% vs 8.3%; P = .001).
    1 context sentence
    Summary · context
    This retrospective cohort study included adult patients with T2D at an academic internal medicine clinic who were initiated on semaglutide or dulaglutide.
  12. 12HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, HbA1c below 7% was numerically less frequent with dulaglutide than semaglutide, without a significant difference.

    In plain wordsIn adults with diabetes, dulaglutide and semaglutide did not differ significantly in the proportion reaching HbA1c below 7%.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeHbA1c below 7%
    Study

    n = 120

    Comparator
    Semaglutide
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Measurements

    Responders
    38.3%
    dulaglutide: HbA1c below 7%
    Responders
    53.3%
    semaglutide: HbA1c below 7%

    Source sentences

    Summary
    A higher percentage of patients using semaglutide than those using dulaglutide achieved an HbA1c less than 7% and less than 8% at 52 weeks (< 7%: 53.3% vs 38.3%; P = .100; < 8%: 78.3% vs 68.3%; P = .220).
    1 context sentence
    Summary · context
    This retrospective cohort study included adult patients with T2D at an academic internal medicine clinic who were initiated on semaglutide or dulaglutide.
  13. 13HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, HbA1c below 8% was numerically less frequent with dulaglutide than semaglutide, without a significant difference.

    In plain wordsIn adults with diabetes, dulaglutide and semaglutide did not differ significantly in the proportion reaching HbA1c below 8%.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeHbA1c below 8%
    Study

    n = 120

    Comparator
    Semaglutide
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Measurements

    Responders
    68.3%
    dulaglutide: HbA1c below 8%
    Responders
    78.3%
    semaglutide: HbA1c below 8%

    Source sentences

    Summary
    A higher percentage of patients using semaglutide than those using dulaglutide achieved an HbA1c less than 7% and less than 8% at 52 weeks (< 7%: 53.3% vs 38.3%; P = .100; < 8%: 78.3% vs 68.3%; P = .220).
    1 context sentence
    Summary · context
    This retrospective cohort study included adult patients with T2D at an academic internal medicine clinic who were initiated on semaglutide or dulaglutide.
  14. 14HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, dulaglutide was linked to less HbA1c reduction than semaglutide.

    In plain wordsIn adults with diabetes, dulaglutide was linked to less blood sugar reduction than semaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseAbsolute HbA1c change
    Study

    n = 120

    Comparator
    Semaglutide
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −1.36%
    dulaglutide
    HbA1c change
    −2.15%
    semaglutide

    Source sentences

    Summary
    The absolute change in HbA1c was greater with semaglutide than dulaglutide (-2.15% vs -1.36%; P = .033).
    1 context sentence
    Summary · context
    This retrospective cohort study included adult patients with T2D at an academic internal medicine clinic who were initiated on semaglutide or dulaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 9Current

    28 Oct 2026, 02:03 UTC

    The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    11 Oct 2026, 00:04 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.